.png)
Orbis Medicines
A new era for oral macrocycle drug discovery
Copenhagen, Denmark · Founded 2024 · $93.0M raised
- Headquarters
- Copenhagen
- Employees
- 11–50
- Founded
- 2024
- Business Model
- B2B
- Website
- orbismedicines.com
- Total Funding
- $93.0M
- Last Round
- $93.0M Series BJan 2025
- Rounds
- 1
About
Orbis Medicines is pioneering a new era for oral macrocycle drug discovery using its nGen platform, which systematically designs and tests macrocyclic compounds called nCycles optimized for oral bioavailability and membrane permeability. The company's pipeline targets diseases historically treated with injectable biologics, aiming to provide accessible oral alternatives. Orbis combines high-throughput synthesis, proprietary DNA-encoded libraries of nearly 100 billion compounds, and deep learning to accelerate macrocycle medicine.
Summary
Orbis Medicines is a Biotech company based in Copenhagen, Denmark, founded in 2024. It has raised $93.0M in total across 1 round, most recently a $93.0M Series B round in Jan 2025.
Tech & App Stack
2 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Jan 2025
Similar Companies
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Clinical-stage precision medicine company developing targeted therapies for immune-mediated infla...
San Diego-based clinical stage biopharmaceutical company focused on the development of small mole...
Clinical-stage biopharmaceutical developing precision medicines targeting novel mechanisms to tre...
Clinical-stage precision medicines company using protein-motion-driven drug discovery to design s...
Biotechnology company that discovers and develops medicines for serious, life-threatening disease...